Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech - Technical Analysis -- Ignore unavailable to you. Want to Upgrade?

To: seminole who wrote (304)	4/8/2002 9:06:58 PM
From: rolatzi	Read Replies (1) \| Respond to of 544

I don't think there is much clinical news about ENMD at the AACR. It is more likely that ASCO in May will generate more information about the human trials of Endostatin, Angiostatin and Panzem. That said, I don't know exactly why ENMD did well today except perhaps it was oversold, the nonclinical reports at AACR today were positive, possible announcement of new partnerships soon and perhaps the beginnings of accumulating prior to the ASCO meeting next month. Ro